SYNB1891
- Generic Name
- SYNB1891
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
SYNB1891 is a live, modified strain of the probiotic Escherichia coli Nissle engineered to produce cyclic di-AMP (CDA), a stimulator of the STING (STimulator of INterferon Genes) pathway. SYNB1891 is under investigation in clinical trial NCT04167137 (Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Non-pathogenic E. coli displaying decoy-resistant IL18 mutein boosts anti-tumor and CAR
Immune checkpoint inhibitors, CAR immune cells, natural killer cells, tumor-infiltrating lymphocytes, emerging immunotherapies, current immunotherapy in gastrointestinal malignancies, tumor-targeting bacteria, advancing clostridia, engineered Salmonella and E. coli strains, and probiotic-guided CAR-T cells are highlighted in cancer therapy research.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath